Want to see TSE:CHGX full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
ChitogenX (CHGX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$415.65K
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)1.67
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding83,129,520
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.00
Price to Sales (P/S)0.00
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ChitogenX Business Overview & Revenue Model
Company Description
ChitogenX Inc. is a Canadian biologics firm specializing in orthopaedic and sports medicine. The company is dedicated to the research and development of innovative therapeutic technologies designed to improve the success rates of soft tissue repai...
How the Company Makes Money
ChitogenX makes money through the development, licensing, and sales of its proprietary medical products and technologies. The company's primary revenue streams include direct sales of its chitosan-based products to healthcare providers and institu...
ChitogenX Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -18.00K | -42.00K | -59.00K | -69.00K | -89.00K | -119.00K |
| EBITDA | -1.19M | -670.00K | -4.75M | -3.44M | -2.54M | -2.06M |
| Net Income | -1.55M | -1.55M | -6.23M | -4.92M | -3.77M | -2.49M |
Balance Sheet | ||||||
| Total Assets | 385.00K | 534.00K | 738.00K | 1.12M | 3.28M | 1.29M |
| Cash, Cash Equivalents and Short-Term Investments | 48.00K | 35.00K | 108.00K | 313.00K | 2.38M | 302.00K |
| Total Debt | 4.23M | 3.88M | 5.56M | 5.71M | 4.62M | 2.61M |
| Total Liabilities | 7.75M | 6.71M | 10.58M | 8.23M | 5.08M | 3.69M |
| Stockholders Equity | -7.36M | -6.18M | -9.84M | -7.10M | -1.80M | -2.40M |
Cash Flow | ||||||
| Free Cash Flow | -153.00K | -1.01M | -3.20M | -3.25M | -2.98M | -1.59M |
| Operating Cash Flow | -153.00K | -1.01M | -3.20M | -3.22M | -2.98M | -1.59M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -33.00K | -3.00K | 0.00 |
| Financing Cash Flow | 75.00K | 937.00K | 2.94M | 1.16M | 5.05M | 1.37M |
ChitogenX Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Neutral
100.00
Negative
0.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CHGX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CHGX.
ChitogenX Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | C$415.65K | -0.23 | 21.10% | ― | ― | ― | |
65 Neutral | C$56.62M | 34.34 | 3.31% | ― | -3.44% | -57.64% | |
53 Neutral | C$41.94M | -7.32 | -8.01% | ― | -34.81% | -453.45% | |
45 Neutral | C$12.86M | -2.74 | ― | ― | ― | 28.70% | |
41 Neutral | C$5.13M | -1.98 | ― | ― | ― | ― |
* Healthcare Sector Average
TSE:CHGX
ChitogenX
0.01
0.00
0.00%
TSE:COV
Covalon Technologies
2.05
-0.34
-14.23%
TSE:HEM
Hemostemix
0.07
-0.07
-51.85%
TSE:KNE
Kane Biotech
0.03
-0.02
-37.50%
TSE:MBX
Microbix Biosystms
0.31
0.01
3.39%
TSE:QPT
Quest Pharmatech
0.02
-0.02
-55.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―